Sarepta Lands a Valuable Priority Review Voucher on Exondys 51 OK

The FDA has issued a priority review voucher to Sarepta, which it’s already been hawking to deep-pocket drug developers.

The biotech won the PRV — good to anyone who buys it for a speedy agency review four months shorter than the norm — after winning approval for eteplirsen. The drug is now being sold for $300,000 a year as Exondys 51, the first drug approved for Duchenne muscular dystrophy in the US.

MORE ON THIS TOPIC